BioSig Technologies Inc Stock Price, News & Analysis

BioSig Technologies (Nasdaq: BSGM) will present its latest software for arrhythmia care at the 2021 Stanford Biodesign New Arrhythmia Technologies Retreat on July 27. The presentation will showcase advancements in the PURE EP(tm) System, designed to improve signal fidelity and procedural efficiency in electrophysiology. Since the targeted commercial launch in 2020, 55 physicians have conducted over 950 patient cases using the system, which has received FDA 510(k) clearance. Atrial fibrillation affects over 33 million globally, highlighting the software's potential impact in addressing this growing healthcare challenge.

BioSig Technologies (NASDAQ: BSGM) announced that data from its PURE EP(tm) System will be presented at the Heart Rhythm 2021 convention in Boston from July 28-31, 2021. Two significant presentations include "Post-Ablation Bipolar Voltage By PURE EP(tm) As a Marker Of Transmural Lesion" and "Atrial Unipolar Electrogram Filtering to Better Delineate EGM Amplitude During Radiofrequency Ablation." The PURE EP(tm) System has received FDA 510(k) clearance, with over 950 patient cases completed across multiple clinical sites. The company aims to enhance procedural efficiency in electrophysiology.

BioSig Technologies (Nasdaq: BSGM) announced its participation in the Heart Rhythm 2021 convention, scheduled for July 28-31, 2021, in Boston, MA. The company will showcase its PURE EP(tm) System, a cutting-edge signal processing platform designed for cardiac arrhythmia care. In April 2021, BioSig completed the enrollment of 51 patients for a clinical trial on various arrhythmia cases, including atrial fibrillation. The PURE EP(tm) System has received FDA 510(k) clearance and has been utilized in over 940 patient cases by 52 physicians across multiple sites.

BioSig Technologies, Inc. (Nasdaq: BSGM) announced that Natasha Drapeau, Executive Vice President, will present at the LD Micro Invitational XI on June 8, 2021, at 5 PM ET. The company is focused on its PURE EP™ System, which enhances signal fidelity for cardiac procedures. With 52 physicians using the system on approximately 900 cases across nine sites, BioSig received FDA 510(k) clearance and began commercialization in 2020. The event, featuring around 180 companies, runs from June 8-10, 2021.

BioSig Technologies, Inc. (Nasdaq: BSGM) announced that Executive Vice President Natasha Drapeau will present at the Jefferies Virtual Healthcare Conference on June 3, 2021, at 2 pm ET. The presentation will cover the company's innovative PURE EP™ System, which enhances diagnostic signal acquisition for cardiac ablation procedures. This system aims to improve procedural efficacy against cardiac arrhythmias, affecting millions globally. BioSig commenced commercialization in 2020, achieving FDA 510(k) clearance and securing sales with major healthcare providers.

BioSig Technologies, Inc. (Nasdaq: BSGM) announced that CEO Ken Londoner will present at the Oppenheimer MedTech, Tools & Diagnostics Summit on May 26, 2021, from 8am to 5pm EST. The company's PURE EP™ System, a groundbreaking signal processing platform for cardiac care, has been used in over 850 patient cases by 48 physicians across 9 clinical sites. BioSig is focused on enhancing ECG and intra-cardiac signal fidelity, crucial for electrophysiology procedures.

BioSig Technologies (NASDAQ: BSGM) has increased its patient case goal for the PURE EP™ System from 1000 to at least 1500 by the end of 2021. So far, 44 physicians have completed over 800 arrhythmia patient cases across nine medical centers, including the Mayo Clinic and University of Pennsylvania. The Texas Cardiac Arrhythmia Institute leads with over 300 cases. The Company anticipates steady procedural growth and aims to establish 20 installation sites by year-end. Atrial fibrillation affects millions, highlighting the demand for BioSig's innovative technology.

BioSig Technologies, Inc. (Nasdaq: BSGM) announced that CEO Ken Londoner will deliver a keynote update at the Wall Street Conference on May 5, 2021, at 12:05 pm ET in West Palm Beach, Florida. The event will feature twelve companies from the MedTech and biotech sectors. BioSig’s PURE EP™ System, aimed at enhancing electrophysiology procedures, has received FDA 510(k) clearance and has been utilized in over 800 patient cases across nine clinical sites. With cardiac arrhythmias affecting millions, this technology could significantly impact patient care.

BioSig Technologies (BSGM) announced that the PURE EP System is now being utilized by Mayo Clinic in Phoenix, Arizona for cardiac arrhythmia treatments. This marks the second installation of the technology, following its use in Florida since January 2020. The PURE EP System enhances signal fidelity and is part of a 30-day clinical evaluation led by experienced electrophysiologists. Over 660 cases have been documented using this technology across nine clinical sites, supporting BioSig's growth in the medical technology sector.